Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Animuscure Inc. is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio demonstrates a distribution of work, as these actions are spread across 4 distinct art units. This indicates the company is pursuing technical claims across multiple units.
The prosecution involves several distinct examiners, with Nicola Maria Bauer identified as the busiest examiner for the portfolio with 1 pending office action. The parity between the workload and the number of officials indicates that each matter is being handled by a different person.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
| NEAGU, IRINA | 1 | 46.8% | +57.3% |
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +60.8% |
| DAVIS, RUTH A | 1 | 60.8% | +31.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250629 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROMUSCULAR DISEASES COMPRISING CDO PROTEIN OR GENE ENCODING SAME | VYAS, KEYUR ANILKUMAR | 6d |
| 18248648 | COMPOSITION FOR PREVENTING OR TREATING NEUROMUSCULAR DISEASE, COMPRISING PRMT1 PROTEIN OR GENE ENCODING SAME | DAVIS, RUTH A | 70d |
| 18557729 | COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE, COMPRISING OXICAM-BASED COMPOUND | NEAGU, IRINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250629 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROMUSCULAR DISEASES COMPRISING CDO PROTEIN OR GENE ENCODING SAME | VYAS, KEYUR ANILKUMAR | 6d |
| 18248648 | COMPOSITION FOR PREVENTING OR TREATING NEUROMUSCULAR DISEASE, COMPRISING PRMT1 PROTEIN OR GENE ENCODING SAME | DAVIS, RUTH A | 70d |
| 18562564 | COMPOSITION COMPRISING INOTODIOL FOR PREVENTION OR TREATMENT OF MUSCULAR DISEASE | BAUER, NICOLA MARIA | — |
| 18557729 | COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE, COMPRISING OXICAM-BASED COMPOUND | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1629 | 1 |
| 1637 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562564 | COMPOSITION COMPRISING INOTODIOL FOR PREVENTION OR TREATMENT OF MUSCULAR DISEASE | BAUER, NICOLA MARIA | 1621 | §103 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18557729 | COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE, COMPRISING OXICAM-BASED COMPOUND | NEAGU, IRINA | 1629 | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18250629 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROMUSCULAR DISEASES COMPRISING CDO PROTEIN OR GENE ENCODING SAME | VYAS, KEYUR ANILKUMAR | 1637 | §103§112 | Final Rejection | 6d | Pending | Apr 26, 2023 |
| 18248648 | COMPOSITION FOR PREVENTING OR TREATING NEUROMUSCULAR DISEASE, COMPRISING PRMT1 PROTEIN OR GENE ENCODING SAME | DAVIS, RUTH A | 1699 | §103§112 | Final Rejection | 70d | Pending | Apr 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial